Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crotaline snake antivenom - Instituto Bioclon/Rare Disease Therapeutics

Next Previous
Drug Profile

Crotaline snake antivenom - Instituto Bioclon/Rare Disease Therapeutics

Alternative Names: Anavip; Crotalidae immune F(ab)2 (equine); Crotalidae snake antivenom - Instituto Bioclon/Rare Disease Therapeutics

Latest Information Update: 07 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Instituto Bioclon
  • Developer Instituto Bioclon; Rare Disease Therapeutics
  • Class Antivenins; Fab fragments
  • Mechanism of Action Protein inhibitors; Viper venom inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Snake venom poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Snake venom poisoning

Most Recent Events

  • 05 Apr 2021 The US FDA approves crotaline snake antivenom for Snake venom poisoning (In neonates, In infants, In children, In adolescent, In adults) by North American Pit Vipers including rattlesnake, copperhead and cottonmouth
  • 08 Oct 2018 Launched for Snake venom poisoning (In neonates, In infants, In children, In adolescent, In adults) in USA (IV)
  • 20 Jun 2005 Phase-II clinical trials in Snake venom poisoning in USA (IV) (NCT00868309)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top